← Back to Search


Non-fluoride vs Fluoride Toothpaste for Tooth Decay

Phase 2
Waitlist Available
Research Sponsored by Colgate Palmolive
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Willingness and ability to use the assigned products according to instructions, availability for all appointments and likelihood of completing the clinical trial
Children ages 10-14 years at baseline
Screening 3 weeks
Treatment Varies
Follow Up one year
Awards & highlights

Study Summary

This trial will compare the safety and effectiveness of a non-fluoride toothpaste to a fluoride toothpaste in children aged 10-14.

Who is the study for?
This trial is for children aged 10-14 with good general health, who have at least two active caries lesions but not severe caries on five or more teeth. They must be able to follow the study's product use instructions and commit to all appointments. Kids with severe periodontal disease, recent participation in another clinical study, pregnancy, orthodontic treatments on multiple teeth, cognitive/motor impairments, or allergies to arginine/oral care products are excluded.Check my eligibility
What is being tested?
The trial tests the safety and effectiveness of COL101 (arginine) non-fluoride toothpaste in preventing cavities compared to a standard fluoride toothpaste over one year. Children will receive either an 8%, 4%, or 1.5% arginine dentifrice or a control toothpaste containing 0.24% sodium fluoride.See study design
What are the potential side effects?
Potential side effects may include allergic reactions specific to arginine or other ingredients in the tested products since these are oral care items designed for regular use; however, significant side effects are not commonly expected from such products.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I am committed to following the trial's treatment plan and attending all appointments.
I am between 10 and 14 years old.
My second permanent molars have started to come in.
I have two or more active tooth cavities and a history of tooth decay.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one year
This trial's timeline: 3 weeks for screening, Varies for treatment, and one year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The primary efficacy endpoint will be the incremental subject-wise Decayed Missing Filled Surfaces (DMFS) score after one year of product use
Secondary outcome measures
Clinically significant change in International Caries Detection and Assessment System (ICDAS) severity scores between the baseline and the six-month and one-year examinations and between the six-month and one-year examinations.
Clinically significant changes indicating caries progression are changes in ICDAS severity values from 0 to 2 or higher, from 1 or 2 to 3 or higher, or from 3 or 4 to 5 or 6.
Clinically significant changes indicating caries regression are changes in ICDAS severity values from 2 or higher to 0 or 1.
+2 more

Trial Design

4Treatment groups
Experimental Treatment
Active Control
Group I: 8.0% Arginine DentifriceExperimental Treatment1 Intervention
Group II: 4.0% Arginine DentifriceExperimental Treatment1 Intervention
Group III: 1.5% Arginine DentifriceExperimental Treatment1 Intervention
Group IV: 0.24% Sodium Fluoride DentifriceActive Control1 Intervention
First Studied
Drug Approval Stage
How many patients have taken this drug
Not yet FDA approved
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Colgate PalmoliveLead Sponsor
86 Previous Clinical Trials
15,418 Total Patients Enrolled
Maria E Ryan, DDS PhDStudy DirectorColgate-Palmolive Company

Media Library

1.5% Arginine Dentifrice (Other) Clinical Trial Eligibility Overview. Trial Name: NCT04750902 — Phase 2
Tooth Decay Research Study Groups: 0.24% Sodium Fluoride Dentifrice, 1.5% Arginine Dentifrice, 4.0% Arginine Dentifrice, 8.0% Arginine Dentifrice
Tooth Decay Clinical Trial 2023: 1.5% Arginine Dentifrice Highlights & Side Effects. Trial Name: NCT04750902 — Phase 2
1.5% Arginine Dentifrice (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04750902 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is 1.5% Arginine Dentifrice a safe product for human use?

"Because this is a Phase 2 trial, and thus there is only some data supporting safety but not efficacy, we have estimated the 1.5% Arginine Dentifrice to be a 2 on our safety scale."

Answered by AI

Does this experiment blaze any new territory?

"1.5% Arginine Dentifrice is being studied in 20 clinical trials in 27 cities and 12 countries. Baxter Healthcare Corporation first ran a trial for 1.5% Arginine Dentifrice in 2007, which completed Phase 4 drug approval in 2007 with 4640 patients. Since then, 134 trials have been completed."

Answered by AI

Will this trial be testing minors?

"In order to participate in this research, potential candidates must be aged 10-14. Out of the 67 ongoing studies, this is one of 40 that specifically looks at this age range."

Answered by AI

In how many different locations are subjects being recruited for this hospital-based research?

"There are 11 total sites for this study, 8 of which are enrolling patients. These 8 locations are Indiana University School of Dentistry in Indianapolis, Loma Linda University School of Dentistry in Loma Linda, and UT Health San Antonio School of Dentistry in San Antonio, among others."

Answered by AI

What are the most up-to-date findings on the effects of 1.5% Arginine Dentifrice?

"Over the course of 134 completed studies since 2007, 1.5% Arginine Dentifrice has been investigated. There are 20 ongoing trials recruiting patients, a majority of which are based in Indianapolis, Indiana."

Answered by AI

What does 1.5% Arginine Dentifrice help to treat?

"Arginine Dentifrice, at a concentration of 1.5%, is often used to treat pituitary dwarfism. However, it has also been clinically shown to be effective against other conditions such as enzymes, pituitary stimulant, and enamel caries."

Answered by AI

Who else is applying?

What state do they live in?
New York
What portion of applicants met pre-screening criteria?
Met criteria
~480 spots leftby Apr 2025